Assessing the Ompact of Neutral Pelvic Positioning on Bone Repositioning Quality in Pelvic Radiotherapy Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Setup with neutral pelvic positioning technique: Setup with neutral pelvic positioning technique (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT Mega Voltage Computed Tomography)
Standard setup: Standard setup (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT)
Study summary
This study explores whether achieving a neutral pelvic position improves bone repositioning quality for patients undergoing pelvic radiotherapy. While Intensity-Modulated Radiotherapy (IMRT) and Image-Guided Radiotherapy (IGRT) have enhanced target volume precision and reduced side effects, effective patient positioning remains crucial. However, rotational adjustments are limited without a specialized robotic table. Current immobilization devices, customizable or not, show limited impact on positioning accuracy, with mixed results on the use of knee and foot supports. A pilot study identified significant rotational variation, and to address this, a "glute bridge" maneuver is proposed to ensure a neutral pelvic position. This randomized study will evaluate the impact of this maneuver on positioning quality when combined with immobilization and skin markers.
Eligibility
Primary outcome measure(s)
- The rate of images with RX > 3° will be calculated for each patient as the number of sessions with a repositioning image where RX is > 3°, relative to the total number of sessions performed. — At to 3 months
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre Leon Berard | Lyon | France | |
| Institut de Cancérologie de Lorraine | Nancy | France | |
| Centre Eugène Marquis | Rennes | France | |
| Institut de Cancérologie de l'Ouest - Saint-Herblain | Saint-Herblain | France |
More Centre Leon Berard trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06687200 on ClinicalTrials.gov ↗ ← All trials in France